These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 8809029

  • 1. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
    Kelly JJ, Barnes PJ, Giembycz MA.
    Biochem J; 1996 Sep 01; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
    [Abstract] [Full Text] [Related]

  • 2. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ, Barnes PJ, Giembycz MA.
    Br J Pharmacol; 1998 May 01; 124(1):129-40. PubMed ID: 9630352
    [Abstract] [Full Text] [Related]

  • 3. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
    Souness JE, Rao S.
    Cell Signal; 1997 May 01; 9(3-4):227-36. PubMed ID: 9218122
    [Abstract] [Full Text] [Related]

  • 4. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
    Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ.
    Mol Pharmacol; 1996 Oct 01; 50(4):891-9. PubMed ID: 8863835
    [Abstract] [Full Text] [Related]

  • 5. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson JA.
    Br J Pharmacol; 1996 Jun 01; 118(3):649-58. PubMed ID: 8762090
    [Abstract] [Full Text] [Related]

  • 6. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
    Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, Torphy TJ.
    J Pharmacol Exp Ther; 1995 Jun 01; 273(3):1396-402. PubMed ID: 7791113
    [Abstract] [Full Text] [Related]

  • 7. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
    Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ.
    J Pharmacol Exp Ther; 1995 May 01; 273(2):674-9. PubMed ID: 7752069
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
    Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, Pillar JS, Shirley JT, Umland JP, Watson JW.
    J Med Chem; 1996 Jan 05; 39(1):120-5. PubMed ID: 8568798
    [Abstract] [Full Text] [Related]

  • 10. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
    Collado MC, Beleta J, Martinez E, Miralpeix M, Domènech T, Palacios JM, Hernández J.
    Br J Pharmacol; 1998 Mar 05; 123(6):1047-54. PubMed ID: 9559885
    [Abstract] [Full Text] [Related]

  • 11. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
    Souness JE, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman MN, Ashton MJ, Karlsson JA.
    Br J Pharmacol; 1995 May 05; 115(1):39-46. PubMed ID: 7647982
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.
    Cooper N, Teixeira MM, Warneck J, Miotla JM, Wills RE, Macari DM, Gristwood RW, Hellewell PG.
    Br J Pharmacol; 1999 Apr 05; 126(8):1863-71. PubMed ID: 10372831
    [Abstract] [Full Text] [Related]

  • 14. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
    Thompson WJ, Ashikaga T, Kelly JJ, Liu L, Zhu B, Vemavarapu L, Strada SJ.
    Biochem Pharmacol; 2002 Feb 15; 63(4):797-807. PubMed ID: 11992650
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CDP840: a novel inhibitor of PDE-4.
    Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lumb S, Huang Z, Howat D, Allen R, Merriman M, Walls J, Daniel T, Hughes B, Laliberte F, Higgs GA, Owens RJ.
    Cell Biochem Biophys; 1998 Feb 15; 29(1-2):113-32. PubMed ID: 9631241
    [Abstract] [Full Text] [Related]

  • 18. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL, Showell HJ, Fisher DA, Pazoles CJ, Watson JW, Turner CR, Cheng JB.
    J Pharmacol Exp Ther; 1996 Sep 15; 278(3):1356-61. PubMed ID: 8819523
    [Abstract] [Full Text] [Related]

  • 19. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.
    Souness JE, Villamil ME, Scott LC, Tomkinson A, Giembycz MA, Raeburn D.
    Br J Pharmacol; 1994 Apr 15; 111(4):1081-8. PubMed ID: 8032594
    [Abstract] [Full Text] [Related]

  • 20. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN, Shiloh AO, Sauermelch CF, Sulpizio A, Michell MP, Cieslinski LB, Torphy TJ, Ohlstein EH.
    J Cereb Blood Flow Metab; 1997 Feb 15; 17(2):210-9. PubMed ID: 9040501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.